Senti Biosciences Holdings (SNTI) Return on Capital Employed (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Return on Capital Employed of 181.09% for Q4 2025, down 8666.0% year-over-year from 2.11% in Q4 2024, and down 32.69% quarter-over-quarter from 136.48% in Q3 2025.
Senti Biosciences Holdings (SNTI) Return on Capital Employed (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Return on Capital Employed history runs 5 years deep, the most recent figure standing at 181.09% for Q4 2025.
- In Q4 2025, Return on Capital Employed fell 8666.0% year-over-year to 181.09%; the TTM figure through Dec 2025 stood at 181.09% (down 8666.0% YoY), while the FY2025 annual figure was 113.58%, down 4967.0% from the prior year.
- Return on Capital Employed for Q4 2025 stood at 181.09%, down from 136.48% in the prior quarter.
- The five-year high for Return on Capital Employed was 16.23% in Q4 2021, with the low at 181.09% in Q4 2025.
- The 5-year median for Return on Capital Employed is 76.82% (2025), against an average of 74.09%.
- Peak annual rise in Return on Capital Employed reached 1611 bps in 2025, while the deepest fall reached 8666 bps in 2025.
- Senti Biosciences Holdings' Return on Capital Employed stood at 16.23% in 2021, then slumped by 140 bps to 38.95% in 2022, then tumbled by 111 bps to 82.09% in 2023, then fell by 15 bps to 94.44% in 2024, then sank by 92 bps to 181.09% in 2025.
- Business Quant data shows SNTI's Return on Capital Employed at 181.09% in Q4 2025, 136.48% in Q3 2025, and 98.33% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Senti Biosciences Holdings | 12.06 Mn | 12.06 Mn | - | -253.31% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -181.09% |
| Sep 30, 2025 | -136.48% |
| Jun 30, 2025 | -98.33% |
| Mar 31, 2025 | -76.82% |
| Dec 31, 2024 | -94.44% |
| Sep 30, 2024 | -100.50% |
| Jun 30, 2024 | -107.90% |
| Mar 31, 2024 | -92.92% |
| Dec 31, 2023 | -82.09% |
| Sep 30, 2023 | -71.19% |
| Jun 30, 2023 | -43.42% |
| Mar 31, 2023 | -43.15% |
| Dec 31, 2022 | -38.95% |
| Sep 30, 2022 | -28.96% |
| Jun 30, 2022 | -24.55% |
| Mar 31, 2022 | -22.56% |
| Dec 31, 2021 | -16.23% |